Anvisa approved the application of Comirnaty, a vaccine for Covid-19, from the company Pfizer in children and adolescents. The measure took place through the authorization, last Monday (5), of changing the dose of the vaccine. This change was requested in June/2022 and will result in the inclusion in the product insert of the recommendation for applying a booster dose to the primary vaccination schedule in children from 5 years old and adolescents.
The application of the booster dose (third dose) was already authorized for those over 18 years old.
For the authorization, Anvisa evaluated clinical data sent by the company and concluded that the benefits of changing the dosage outweigh the risks of applying the booster dose in this age group.
Vaccines against Covid-19 have generally shown a decline in antibodies over time, justifying the periodic assessment of the need to apply booster doses, with the aim of maintaining adequate levels of antibodies capable of neutralizing the causative virus. of the disease.
The Comirnaty vaccine in use in Brazil has been registered with Anvisa since February 23, 2021, with indication for immunization of a wide age range, starting from 6 months of age.
It is recommended that all people keep their booster doses up to date in order to improve protection against severe cases and deaths from Covid-19.
(Posted by João Guimarães)
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
